SCHEMBL6237784

SCHEMBL6237784

CC(C)OCc1ccco1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.52
SLC1A3 P43003 1/20 0.50
SLC1A2 P43004 1/20 0.50
SLC1A1 P43005 1/20 0.50
LMNA P02545 1/20 0.47
GAA P10253 2/20 0.46
CYP2D6 P10635 1/20 0.43
HPGD P15428 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TP53 P04637 2/20 0.41
KMT2A Q03164 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
MAPT P10636 2/20 0.38
POLB P06746 2/20 0.38
MEN1 O00255 1/20 0.38
RAB9A P51151 1/20 0.38
CYP2C19 P33261 1/20 0.38
ACACB O00763 1/20 0.37
MAPK1 P28482 2/20 0.37
HSD17B10 Q99714 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1845031 0.84 ALDH1A1 (0.53) ALDH1A1SLC1A3SLC1A2SLC1A1LMNA
SCHEMBL17320587 0.82 ALDH1A1 (0.47) ALDH1A1SLC1A3SLC1A2SLC1A1LMNA
SCHEMBL28835773 0.82 ALDH1A1 (0.47) ALDH1A1SLC1A3SLC1A2SLC1A1LMNA
SCHEMBL19251019 0.81 ALDH1A1 (0.46) ALDH1A1SLC1A3SLC1A2SLC1A1LMNA
SCHEMBL4620314 0.81 ALDH1A1 (0.50) ALDH1A1SLC1A3SLC1A2SLC1A1LMNA
SCHEMBL4620318 0.81 ALDH1A1 (0.50) ALDH1A1SLC1A3SLC1A2SLC1A1LMNA
SCHEMBL31321607 0.80 ALDH1A1 (0.49) ALDH1A1SLC1A3SLC1A2SLC1A1LMNA
SCHEMBL25860125 0.80 ALDH1A1 (0.42) ALDH1A1SLC1A3SLC1A2SLC1A1LMNA
SCHEMBL23089952 0.80 SLC1A3 (0.48) ALDH1A1SLC1A3SLC1A2SLC1A1LMNA
SCHEMBL11254941 0.78 ALDH1A1 (0.47) ALDH1A1SLC1A3SLC1A2SLC1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119186595-A Method for preparing furfuryl alcohol and isopropyl furfuryl ether by high-efficiency selective conversion of furfural 淮阴师范学院 2024-12-27 CN claimed
CN-116351416-B Non-noble metal catalyst for preparing furfurether by etherification of furfuraldehyde, and preparation method and use method thereof 郑州大学 2024-08-13 CN claimed
CN-117816197-A Sulfonic acid functionalized zirconium-carbon coordination catalyst, preparation method and application thereof in synthesis of furyl diether liquid fuel 淮阴师范学院 2024-04-05 CN claimed
WO-2013013829-A1 HEALABLE COMPOSITE MATERIALS BASED ON REVERSIBLE BINDER SYSTEMS EADS DEUTSCHLAND GMBH (DE) 2013-01-31 WO claimed
EP-2551093-A1 Healable composite materials based on reversible binder systems EADS Deutschland GmbH (DE) 2013-01-30 EP claimed
CN-119186595-A Method for preparing furfuryl alcohol and isopropyl furfuryl ether by high-efficiency selective conversion of furfural 淮阴师范学院 2024-12-27 CN disclosed
CN-119186595-A Method for preparing furfuryl alcohol and isopropyl furfuryl ether by high-efficiency selective conversion of furfural 淮阴师范学院 2024-12-27 CN disclosed
CN-119186595-A Method for preparing furfuryl alcohol and isopropyl furfuryl ether by high-efficiency selective conversion of furfural 淮阴师范学院 2024-12-27 CN disclosed
US-20240367156-A1 IRON-COBALT-BASED MAGNETICALLY RECOVERABLE CATALYSTS AND METHOD OF PREPARATION THEREOF KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2024-11-07 US disclosed
CN-118594602-A Preparation method of cellulose carbon modified Zr/beta catalyst and application of cellulose carbon modified Zr/beta catalyst in catalyzing xylose to directly convert gamma-valerolactone 昆明理工大学 2024-09-06 CN disclosed
CN-116351416-B Non-noble metal catalyst for preparing furfurether by etherification of furfuraldehyde, and preparation method and use method thereof 郑州大学 2024-08-13 CN disclosed
CN-117816197-A Sulfonic acid functionalized zirconium-carbon coordination catalyst, preparation method and application thereof in synthesis of furyl diether liquid fuel 淮阴师范学院 2024-04-05 CN disclosed
US-20070117795-A1 Methods and compositions of novel triazine compounds DR. REDDY'S LABORATORIES LTD. (IN) 2007-05-24 US disclosed
US-20070099874-A1 Methods and compositions of novel triazine compounds REDDY US THERAPEUTICS, INC. (US) 2007-05-03 US disclosed
US-7169785-B2 Methods and compositions of novel triazine compounds REDDY US THERAPEUTICS, INC. (US) 2007-01-30 US disclosed
US-7169785-B2 Methods and compositions of novel triazine compounds REDDY US THERAPEUTICS, INC. (US) 2007-01-30 US disclosed
US-20050258553-A1 Method for the organometallic production of organic intermediate products comprising carbon-heteroatom bonds achieved by the deprotonation of heteroatoms ARCHIMICA GMBH (DE) 2005-11-24 US disclosed
EP-1537125-A1 METHOD FOR THE ORGANOMETALLIC PRODUCTION OF ORGANIC INTERMEDIATE PRODUCTS COMPRISING CARBON-HETEROATOM BONDS ACHIEVED BY THE DEPROTONATION OF HETEROATOMS Clariant GmbH (DE) 2005-06-08 EP disclosed
WO-2004024737-A1 METHOD FOR THE ORGANOMETALLIC PRODUCTION OF ORGANIC INTERMEDIATE PRODUCTS COMPRISING CARBON-HETEROATOM BONDS ACHIEVED BY THE DEPROTONATION OF HETEROATOMS CLARIANT GMBH (DE) 2004-03-25 WO disclosed
US-4496767-A REARRANGEMENT, ESTERIFICATION AND REDUCTION OF A FURAN-CARBINOL SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1985-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099874-A1 Methods and compositions of novel triazine compounds AREG, TGFB1, PTGIS ALDH1A1 4407/4885SLC1A3 4626/4885SLC1A2 4496/4885
US-20050258553-A1 Method for the organometallic production of organic intermediate products comprising carbon-heteroatom bonds achieved by the deprotonation of heteroatoms IGLV6-57, ICMT, INTS6 ALDH1A1 883/4885SLC1A3 1765/4885SLC1A2 1068/4885
US-20070117795-A1 Methods and compositions of novel triazine compounds AREG, TGFB1, PTGIS ALDH1A1 4407/4885SLC1A3 4626/4885SLC1A2 4496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.